MedTrace Logo

Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection

NCT05452317 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2023-04-13

No results posted yet for this study

Summary

This study investigates the burden of disease among kidney transplant recipients that have developed Chronic Active Antibody Mediated Rejection (caAMR) compared with kidney transplant recipients that have not developed caAMR

Conditions

  • Antibody-mediated Rejection in Kidney Transplant

Interventions

OTHER

Chronic active AMR group

Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.

OTHER

Non-Chronic active AMR group

Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.

Sponsors & Collaborators

  • UBC Late Stage (UK) Ltd.

    collaborator UNKNOWN

  • CSL Behring

    lead INDUSTRY

Principal Investigators

  • Songkai Yan · CSL Behring

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-14
Primary Completion
2023-04-04
Completion
2023-04-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05452317 on ClinicalTrials.gov